
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROMETHAZINE HYDROCHLORIDE PLAIN | ANI Pharmaceuticals | N-008381 DISCN | 1982-01-01 | 2 products, RLD |
| PHENERGAN | Delcor Asset | N-007935 DISCN | 1982-01-01 | 3 products, RLD |
| PHENERGAN | Mylan | N-010926 DISCN | 1982-01-01 | 2 products, RLD |
| PHENERGAN | Mylan | N-011689 DISCN | 1982-01-01 | 1 products, RLD |
| PHENERGAN | Wyeth | N-008857 DISCN | 1982-01-01 | 2 products |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHENERGAN W/ CODEINE | ANI Pharmaceuticals | N-008306 DISCN | 1984-04-02 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHENERGAN VC W/ CODEINE | ANI Pharmaceuticals | N-008306 DISCN | 1984-04-02 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHENERGAN VC | ANI Pharmaceuticals | N-008604 DISCN | 1984-04-02 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE | ANI Pharmaceuticals | N-011265 RX | 1984-04-02 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MEPERGAN | Hikma Pharmaceuticals | N-011730 DISCN | 1982-01-01 | 1 products |
Brand Name | Status | Last Update |
|---|---|---|
| dextromethorphan hydrobromide and promethazine hydrochloride | ANDA | 2024-06-05 |
| phenadoz | ANDA | 2021-03-01 |
| phenergan | ANDA | 2025-06-30 |
| prometh with codeine | ANDA | 2012-01-24 |
| promethazine | ANDA | 2022-10-08 |
| promethazine and codeine | ANDA | 2009-08-21 |
| promethazine dm | ANDA | 2025-05-31 |
| promethazine hci | ANDA | 2024-02-22 |
| promethazine hcl | ANDA | 2019-11-26 |
| promethazine hcl promethazine hydrochloride | 2006-11-27 |
Code | Description |
|---|---|
| J2180 | Injection, meperidine and promethazine hcl, up to 50 mg |
| J2550 | Injection, promethazine hcl, up to 50 mg |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 26 | 28 | 95 | 106 | 63 | 312 |
| Healthy volunteers/patients | — | — | — | 75 | 1 | 1 | 2 | 15 | 93 |
| Essential hypertension | D000075222 | — | I10 | 4 | 4 | 20 | 13 | 7 | 48 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 3 | 7 | 10 | 13 | 3 | 34 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 1 | 8 | 12 | 6 | 30 |
| Covid-19 | D000086382 | — | U07.1 | 5 | 12 | 9 | 3 | 2 | 27 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 2 | 3 | 5 | 12 | 7 | 27 |
| Proteinuria | D011507 | — | R80 | 1 | 4 | 6 | 7 | 7 | 24 |
| Nausea | D009325 | — | R11.0 | — | 3 | 5 | 7 | 8 | 23 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 3 | 4 | 10 | 3 | 21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 8 | 14 | 1 | — | 2 | 24 |
| Lymphoma | D008223 | — | C85.9 | 10 | 14 | 1 | — | 1 | 24 |
| Multiple myeloma | D009101 | — | C90.0 | 8 | 12 | 3 | — | 1 | 22 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 10 | 1 | — | 1 | 17 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 8 | 2 | — | 2 | 15 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 8 | 1 | 5 | — | — | 14 |
| Plasma cell neoplasms | D054219 | — | — | 5 | 7 | 2 | — | 1 | 14 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 5 | 5 | — | 1 | 13 |
| Lung neoplasms | D008175 | — | C34.90 | 4 | 7 | 2 | — | 1 | 11 |
| Infections | D007239 | EFO_0000544 | — | 3 | 4 | 2 | — | 2 | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 10 | 10 | — | — | 2 | 20 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 8 | 6 | — | — | 1 | 14 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 5 | — | — | 1 | 10 |
| Hematologic neoplasms | D019337 | — | — | 2 | 6 | — | — | 1 | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 7 | — | — | — | 8 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 2 | — | — | — | 8 |
| Hepatitis b | D006509 | — | — | 1 | 5 | — | — | 2 | 8 |
| B-cell lymphoma | D016393 | — | — | 6 | 2 | — | — | — | 8 |
| Fibrosis | D005355 | — | — | 3 | 6 | — | — | — | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 3 | — | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 5 | — | — | — | 1 | 6 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 3 | — | — | — | 2 | 5 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 3 | — | — | — | 1 | 4 |
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Pure autonomic failure | D054970 | — | — | 3 | — | — | — | — | 3 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | — | — | — | 1 | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | — | — | 1 | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 2 | — | — | — | — | 2 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 2 | — | — | — | — | 2 |
| Alcohol-related disorders | D019973 | — | F10 | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasomnias | D020447 | — | G47.5 | — | — | — | — | 4 | 4 |
| Dyssomnias | D020920 | — | — | — | — | — | — | 3 | 3 |
| Chronic pain | D059350 | — | — | — | — | — | — | 3 | 3 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 2 | 2 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | — | 2 | 2 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 2 | 2 |
| Rotator cuff injuries | D000070636 | — | M75.1 | — | — | — | — | 2 | 2 |
| Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 2 | 2 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug common name | Promethazine |
| INN | promethazine |
| Description | Promethazine is a tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. It has a role as a H1-receptor antagonist, a sedative, an antiemetic, a local anaesthetic, an antipruritic drug, an anti-allergic agent and an anticoronaviral agent. It is a member of phenothiazines and a tertiary amine. It is a conjugate base of a promethazine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(CN1c2ccccc2Sc2ccccc21)N(C)C |
| PDB | — |
| CAS-ID | 60-87-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL643 |
| ChEBI ID | 8461 |
| PubChem CID | 4927 |
| DrugBank | DB01069 |
| UNII ID | FF28EJQ494 (ChemIDplus, GSRS) |































